logo
Plus   Neg
Share
Email

Eli Lilly: Taltz Shows Efficacy In Phase 4 Study - Quick Facts

Eli Lilly and Company (LLY) said Taltz (ixekizumab), an IL-17A inhibitor, met the primary and all major secondary endpoints in the phase 4 IXORA-R study. The study involved 1,027 patients with moderate to severe plaque psoriasis. At 12 weeks, Taltz showed superiority in the proportion of patients achieving complete skin clearance compared to TREMFYA, a IL-23/p19 inhibitor. The safety data was consistent with prior results.

The company plans to submit detailed data from the study at scientific meetings and in peer-reviewed journals.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Amazon is expanding the aircraft fleet of its air cargo network by leasing 12 additional Boeing 767-300 converted cargo aircraft from Air Transport Services Group Inc. This comes amid increased demand for shipments due to the coronavirus pandemic. These aircraft will join Amazon Air's existing fleet of 70 aircraft to bring its total network to more than 80 aircraft. New York's transit agency The Metropolitan Transportation Authority or MTA has pulled its newest subway cars from service after two cars got detached from a moving train. New York City Transit Interim President Sarah Feinberg launched an investigation into the matter. The entire R179 fleet from Canadian company Bombardier Inc. has been pulled until further notice after the incident in Chambers AMC Entertainment Holdings, Inc., the world's largest theatre chain, said it has substantial doubt in its ability to continue its business as theaters across the world remain closed for months now following coronavirus or Covid-19 pandemic. In a regulatory filing, the company said it is "generating effectively no revenue", and that additional capital, if needed, may not be available.
Follow RTT